Literature DB >> 24476438

Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.

Daniel D Von Hoff, David Goldstein, Markus F Renschler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24476438     DOI: 10.1056/NEJMc1314761

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

Review 1.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Stromal reengineering to treat pancreas cancer.

Authors:  Ingunn M Stromnes; Kathleen E DelGiorno; Philip D Greenberg; Sunil R Hingorani
Journal:  Carcinogenesis       Date:  2014-06-07       Impact factor: 4.944

4.  Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.

Authors:  Majid Momeny; Zivar Alishahi; Haniyeh Eyvani; Fatemeh Esmaeili; Azam Zaghal; Parisa Ghaffari; Javad Tavakkoly-Bazzaz; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2019-09-06       Impact factor: 6.730

5.  Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Michela Capello; Minhee Lee; Hong Wang; Ingrid Babel; Matthew H Katz; Jason B Fleming; Anirban Maitra; Huamin Wang; Weihua Tian; Ayumu Taguchi; Samir M Hanash
Journal:  J Natl Cancer Inst       Date:  2015-05-29       Impact factor: 13.506

Review 6.  Neoadjuvant therapy for localized pancreatic cancer: guiding principles.

Authors:  Amir Fathi; Kathleen K Christians; Ben George; Paul S Ritch; Beth A Erickson; Parag Tolat; Fabian M Johnston; Douglas B Evans; Susan Tsai
Journal:  J Gastrointest Oncol       Date:  2015-08

7.  Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.

Authors:  Asfar S Azmi; Husain Yar Khan; Irfana Muqbil; Amro Aboukameel; Jasper E Neggers; Dirk Daelemans; Amit Mahipal; Gregory Dyson; Mandana Kamgar; Mohammad Najeeb Al-Hallak; Anteneh Tesfaye; Steve Kim; Vinod Shidham; Ramzi M Mohammad; Philip A Philip
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

8.  Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.

Authors:  Yuanfen Liu; Hassan Tamam; Yoon Yeo
Journal:  AAPS PharmSciTech       Date:  2017-10-02       Impact factor: 3.246

Review 9.  Quantitative phenotypic and pathway profiling guides rational drug combination strategies.

Authors:  John C Dawson; Neil O Carragher
Journal:  Front Pharmacol       Date:  2014-05-28       Impact factor: 5.810

Review 10.  Combination therapeutics in complex diseases.

Authors:  Bing He; Cheng Lu; Guang Zheng; Xiaojuan He; Maolin Wang; Gao Chen; Ge Zhang; Aiping Lu
Journal:  J Cell Mol Med       Date:  2016-09-07       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.